Drug intelligence / Profile preview

BC011

Development stage: Preclinical
Lead developer: Dragonboat Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BC011 is a monoclonal antibody (mAb) that targets Tumor Necrosis Factor Receptor Superfamily Member 1B (TNFR2), currently under development by Dragon Boat Pharmaceutical (a subsidiary of Guilin Sanjin). TNFR2 is a member of the TNF receptor superfamily and is predominantly expressed on regulatory T cells (Tregs) and certain tumor cells, where it plays a role in immune evasion and tumor progression. By modulating TNFR2, BC011 aims to disrupt the immunosuppressive environment within tumors, particularly in gastrointestinal cancers such as pancreatic cancer. The drug has received IND approval, positioning it for early-phase clinical evaluation.

Targets

TNFR2 (Tumor necrosis factor receptor superfamily member 1B)

Beyond the preview

Go deeper on BC011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BC011.

Explore the full profile